

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Currently Amended) A method of reducing the accumulation of globotriaosylceramide in a subject diagnosed as having Fabry disease comprising:  
a) administering to the subject ~~a viral or non-viral~~ **an adeno-associated virus (AAV) vector encoding a  $\alpha$ -galactosidase A, wherein the administration of the vector results in targeting of the  $\alpha$ -galactosidase A to the liver** and

b) subsequently administering to the subject a therapeutically effective amount of an exogenously produced natural or recombinant  $\alpha$ -galactosidase A,

such that the accumulation of globotriaosylceramide in the subject is reduced.

2-5. (Canceled)

6. (Previously presented) The method according to claim 1 wherein the  $\alpha$ -galactosidase A is a recombinant  $\alpha$ -galactosidase A.

7-16. (Canceled)

17. (Previously presented) The method of claim 1, wherein the exogenously produced natural or recombinant  $\alpha$ -galactosidase is administered intravenously.

18. (Previously presented) The method of claim 1, wherein the viral or non-viral vector encoding a  $\alpha$ -galactosidase A is administered ex vivo.

19. (Previously presented) The method of claim 1, wherein the viral or non-viral vector encoding a  $\alpha$ -galactosidase A is administered in vivo.